摘要
三阴性乳腺癌(Triple-negative breast cancer,TNBC)是世界上最常见的恶性肿瘤之一,具有独特的病理学特征及高度异质性,较其他乳腺癌亚型易发生转移、恶性程度高、预后差等。抗体偶联药物(Antibody-drug conjugates,ADCs)是一类由单克隆抗体及小分子细胞毒性载体通过连接子偶联而成的有潜力的新型肿瘤靶向药物,直接将细胞毒性物质递送到靶细胞上,在TNBC的临床研究中具有广阔的应用前景。目前,已有多个ADCs被应用于治疗TNBC,本文重点对现阶段ADCs在TNBC中的研究进展进行综述。
Triple-negative Breast Cancer is one of the most commonly diagnosed cancer in the world,and is associated with unique pathological features and high heterogeneity.Compared wiuh other subtypes of breast cancer,it is prone to metastasis,with high degree of malignancy and poor prognosis.Antibody–drug conjugates are new tumor targeted drugs comprised of a monoclonal antibody tethered to a cytotoxic drug via a linker.The ADC is designed to deliver the toxic drugs directly to the target cancer cells.It has broad application prospect in TNBC clinical research.To date,several ADCs have been applied in the treatment of TNBC,this article reviewed the current research progress of ADCs in the treatment of TNBC.
作者
蓝荫香
邱秀梁
方火花
LAN Yin-xiang;QIU Xiu-liang;FANG Huo-hua(Fujian Children′s Hospital,Fuzhou 350011,China;Fujian Branch of Shanghai Children′s Medical Center,Fuzhou 350011,China;College of Clinical Medicine for Obstetrics&Gynecology and Pediatrics,Medical University,Fuzhou 350001,China;FuJian Cancer Hospital,Fuzhou 350014,China;FuJian Provincial Hospital,Fuzhou 350001,China)
出处
《海峡药学》
2023年第11期1-6,共6页
Strait Pharmaceutical Journal
关键词
抗体偶联药物
三阴性乳腺癌
靶向治疗
Antibody-conjugated drugs
Triple negative breast cancer
Targeted therapy
